Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20692061 | 0.92 | P2RY12 (0.45) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL21726069 | 0.92 | P2RY12 (0.55) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL21263848 | 0.91 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL22858552 | 0.90 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6P2RX3 | |
| SCHEMBL19944484 | 0.90 | P2RY12 (0.47) | P2RY12P2RY2P2RY1P2RY6P2RX3 | |
| SCHEMBL19146239 | 0.90 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL20353076 | 0.88 | P2RY12 (0.45) | P2RY12P2RY2P2RY1P2RY6P2RX3 | |
| SCHEMBL24322092 | 0.87 | P2RY12 (0.43) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL24444139 | 0.86 | ADORA1 (0.43) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL21540034 | 0.85 | P2RY12 (0.44) | P2RY12P2RY2P2RY1P2RY6DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2012024776-A1 | BLOCK SYNTHESIS OF OLIGORIBONUCLEOTIDES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002323-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, CD38, NTPCR | P2RY12 1249/4885P2RY2 985/4885P2RY1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.